Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TLSI
Strong SellSinkerTriSalus Life Sciences, Inc. · Healthcare · United States · $297M · Avg Vol: $796K/d
COMPANY DESCRIPTION
TriSalus Life Sciences, Inc. is a medical device company developing innovative drug delivery systems designed to improve outcomes for patients with solid tumors, particularly those resistant to conventional therapies. Its competitive moat is built on proprietary Pressure-Enabled Drug Delivery (PEDD) technology, which aims to overcome biological barriers and enhance targeted therapy penetration. TriSalus is positioned as a specialized innovator in interventional oncology, addressing critical unmet needs in cancer treatment.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.4M | 18.5M | 29.4M | 45.2M | 53.9% | 45.1M | 52.5M | 73.6M | 27.6% |
| EPS | -69.22 | -2.89 | -1.31 | -1.84 | — | -1.33 | — | — | — |
| Shares | 61.4M | 61.4M | 31.3M | 50.0M | -18.6% | 61.6M | — | — | — |
| Debt | 2.0M | 1.6M | 23.6M | 34.4M | 159.8% | 34.4M | — | — | — |
| Equity | -176.3M | -27.1M | -25.9M | -33.9M | — | — | — | — | — |
| Op CF | -32.3M | -50.6M | -40.8M | -18.0M | — | -22.8M | — | — | — |
| Inv CF | -1.8M | -1.6M | -0.3M | -0.8M | — | — | — | — | — |
| Fin CF | 13.5M | 54.6M | 37.9M | 30.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TLSI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TLSI | TriSalus Life Sciences, Inc.(you) | $297M | 20 | Strong Sell |
| RXST | RxSight, Inc. | $293M | 19 | Strong Sell |
| LAB | Standard BioTools Inc. | $252M | 18 | Strong Sell |
| CV | CapsoVision, Inc. | $297M | 13 | Strong Sell |
| MOBI | Mobia Medical, Inc. | $378M | 15 | Strong Sell |
| CATX | Perspective Therapeutics, Inc. | $355M | 12 | Strong Sell |
| PACB | Pacific Biosciences of California, Inc. | $435M | 16 | Strong Sell |
| OFIX | Orthofix Medical Inc. | $392M | 27 | Sell |
| PAIN.V | Vector Science and Therapeutics Corp. | $233M | 8 | Strong Sell |
| APYX | Apyx Medical Corporation | $130M | 18 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.1%